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A phase 1 trial of a candidate human immunodeficiency virus type 1 (HI\'-I) vaccine was done
in 25 healthy seronegative subjects. The antigen, env2-3 (SF2), was a nonglycosylated polypep-
tide representing the gp120 region of the env gene of the HIV-l(SF2) isolate. It was produced
in genetically engineered yeast as a denatured molecule incapable of binding CD4. A synthetic
lipophilic muramyl tripeptide (MTP-PE) was used as an adjuvant. Ten subjects received adju-
vant alone and 15 received 50- or 25O-JLg doses of env2-3 (SF2) administered intramuscularly
in two immunization regimens. In general, adjuvant and vaccine were well tolerated. Antibody
responses to both the homologous antigen, env2-3 (SF2), and antigens from other highly diver-
gent HIV isolates were elicited in the majority of vaccine recipients. However, antibody titers
were low, without neutralizing activity. In 9 of 11 subjects who received the complete vaccine
immunization series, a significant specific T lymphocyte response was observed.
Various experimental approaches have been proposed for
the development of a vaccine against the human immuno-
deficiency virus type 1 (HIV-l) [1-4]. A killed, inactivated,
or attenuated HIV vaccine antigen has the advantage of being
nearly identical to the native virus [1] but is potentially haz-
ardous to produce in large quantities and raises fear of the
presence of infectious particles. Genetically modified vaccinia
virus containing the envelope protein present on the surface
of HIV has been used to vaccinate chimpanzees and humans
[5-8]. Recently, an engineered poliovirus chimera eliciting
broadly reactive HIV-l neutralizing antibodies in rabbits has
been described [9]. An alternative strategy that uses purified
viral proteins or subunits produced by recombinant DNA
methods offers significant manufacturing and safety advan-
tages. Most notably, these vaccines are noninfectious and have
no potential for transmitting disease.
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Our clinical trial was designed to study the safety and im-
munogenicity of env2-3 (SF2) antigen combined with the
muramyl tripeptide-dipalmitoyl phosphatidylethanolamine
(MTP-PE) adjuvant as a subunit HIV-l vaccine in human sub-
jects. Env2-3 (SF2) is a denatured, nonglycosylated polypep-
tide analog ofHIV-l gp120produced in genetically engineered
yeast cells. The external glycoprotein of HIV is pivotal in the
binding of the virus to susceptible cells and the formation of
syncytia in tissue culture systems [10-15]. In addition, affinity
columns prepared with env2-3 (SF2) linked to Sepharose are
able to bind antibodies from HIV-seropositive human sera,
which, when eluted from the column, can neutralize several
isolates of HIV-l [16]. In preclinical studies, various species
of animals immunized with env2-3 (SF2) produced antibod-
ies capable of neutralizing the homologous virus isolate in
vitro [17]. Similar results have been reported by others using
genetically engineered [18] or virus-derived gp120 [19]. Env2-
3 (SF2) does not bind to CD4, thus minimizing concerns about
its potential immunosuppressive effects due to interference
with T cell responses [20]. MTP-PE enhances antibody lev-
els in an manner equivalent to complete Freund's adjuvant
in various experimental animals [21]. The observed responses
were much higher than those obtained with alum.
Methods
Volunteers. Twenty-five healthy men aged 20-60, with no past
or present risk for HIV infection, were enrolled. Their health status
was assessed by a complete medical history, physical examination,
hematology, blood chemistry, and urine analyses. Exclusion criteria
included allergies, asthma of unknown cause, immune suppression
of any kind, chronic debilitating viral infections, cancer, autoim-
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mune disease, and seropositivity for HIV or surface antigen of hep-
atitis B virus (HBsAg). All subjects were advised not to engage in
any risk activity for HIV infection. They were given a certificate
documenting their participation in the study.
Vaccine. Env2-3 (SF2) is a nonglycosylated polypeptide equiva-
lent of the gp120 envelope glycoprotein of the HIV-l SF2 isolate [22,
23] produced in the genetically engineered yeast Saccharomyces
cerevisiae [16,24]. It has a molecular weight of f'\J 56,000. The env2-
3 (SF2) antigen was >95 % pure.
The adjuvant (MTP-PE) is a synthetic muramyl tripeptide cova-
lently linked with dipalmitoyl phosphatidylethanolamine [25, 26].
Squalene (Merck-Schuchardt, Darmstadt, FRG) and Tween 80 (ICI,
Essen, FRG) were included in the adjuvant formulation [21]. The
final vaccine preparation was obtained by emulsifying the antigen
with the adjuvant formulation just before injection.
The study ran from August 1988 to September 1989. The trial
was designed to be a randomized, open-label comparison of two im-
munization schemes: with adjuvant alone (lqo ILglinjection) or with
a low (50 ILglinjection) or a high dose (250 ILglinjection) of env2-3
(SF2) in the same adjuvant. Injections were administered alternately
in the right and left deltoid muscles. Controls were injected with
100 ILg of MTP-PE alone at 0, 4, and 24 weeks (group 1) or 0,4,
8, 12, 16, and 20 weeks (group 2). The three remaining groups re-
ceived 100 ILg of MTP-PE combined with 50 ILg of env2-3 (SF2)
at 0,4, and 24 weeks (group 3), 250 ILg of env2-3 (SF2) at 0, 4,and
24 weeks (group 4), or 250 ILg of env2-3 (SF2) at 0, 4, 8, 12, 16,
and 20 weeks (group 5).
Monitoring ofside effects. All subjects were monitored for 1 h
after injection and reexamined after 24 h. They were asked to re-
cord their local and systemic reactions for 48 h.
Laboratory investigations. Blood and urine specimens were ob-
tained for screening before enrollment and before each injection dur-
ing the study. Analysis included complete blood counts, serum
chemistry evaluations, urinalysis, coagulation tests, lymphocyte sub-
population determination, quantitative immunoglobulin levels (IgG,
IgA, IgM, IgE), and determination of autoantibodies to HBsAg and
to nuclear, gastric, thyroid, smooth muscle, striated muscle, heart
muscle, mitochondria, adrenal, and salivary gland antigens. Uri-
nalysis and hematology were performed 24 h after each injection.
Recombinant HIV-l antigens used for evaluation of immune re-
sponses. In addition to the env2-3 (SF2) antigen from HIV-l(SF2),
equivalent molecules from two other HIV-l isolates, HN/HTLV-
IIIB (human T lymphotropic virus type IIIB) [27] and HIV(Zr6)
[28], were used in serologic assays. These antigens were purified
as described previously [16, 17,29]. Fully glycosylated native gp120
from HIV-l(SF2), referred to as gp120 (SF2), which retains the ability
to bind to CD4, was produced in genetically engineered CHO cells
[30].
Antibodyassays. The levels of antibodies to the immunizing an-
tigen were determined by indirect ELISA [17,31], as was their cross-
reactivity with env2-3 (SF2)-equivalent polypeptides from HN(Zr6)
and HIV/HTLV-I1IB.
The recombinant immunoblot assay (RIBA; Chiron, Emeryville,
CA) HIV 216 strip analysis and the Biotech/Du Pont HIV Western
blot assay (New England Nuclear, Boston) were performed as de-
scribed in the manufacturers' protocols.
Sera were tested for neutralization ofHIV-l(SF2) as described pre-
viously [16, 17].
Peripheral blood mononuclear cell (PBMC)proliferation. Lym-
phoproliferative assaysto detect mitogen and antigen-specificprolifer-
ation were performed following standard protocols [32]. PBMC
recovered from ficoll-hypaque were cultured at lOS/well (0.2
ml/well) in 96-well flat-bottom Costar microplates with 1 ILg/ml mito-
gen, phytohemagglutinin (PHA; Wellcome, Dartford, UK), or 1,
3, and 10 ILg/ml env2-3 (SF2) or gp120 (SF2) antigens. Cell prolifer-
ation was monitored by [3H]thymidine uptake after 3 and 7 days for
PHA and antigen, respectively. Data are expressed as geometric
means of counts per minute of triplicate cultures. A stimulation in-
dex >4 was considered a positive response.
Results
Tolerability
Three volunteers were excluded after the first injection for
study-unrelated abnormalities detected in baseline studies done
earlier the same day: a group 3 subject with IgM paraproteine-
mia, a group 4 subject with familial idiopathic thrombocytope-
nia, and a group 5 subject with iron-deficiency anemia. Two
volunteers experienced injection-related events that led to ex-
clusion after the second administration: a group 1 subject who
experienced vasovagal syncope and a group 4 subject with
a local hypersensitivity reaction to the env2-3 (SF2) antigen
(without MTP-PE) documented by intradermal challenge.
Of 25 total volunteers in adjuvant and vaccine groups, 19
experienced mild local pain lasting up to 24 h after at least
one injection. Of the 15 who received the complete vaccine,
3 had local induration ofthe skin that disappeared after 3-24 h.
Four of the same 15 subjects reported a significant sensa-
tion of fatigue lasting <24 h. Fatigue was not reported in the
two control groups. Two volunteers in the vaccine groups had
fever (axillary 38°C), after one of their immunizations, that
disappeared within 1 day. Four volunteers experienced a mild
headache.
There was no alteration of hematologic, blood chemistry,
or urinalysis values that proved to be study related. No au-
toantibodies were detected, and the levels of all four immu-
noglobulin classes remained stable, indicating the absence of
polyclonal B lymphocyte stimulation. Relative and absolute
CD4 and CD8 T cell values remained unchanged in all fully
immunized subjects.
Immunogenicity of the Vaccine
For the serology and lymphoproliferative assays, we have
included data only from individuals who completed the im-
munization series.
Antibodyresponses. Among the subjects receiving adju-
vant alone, only 1 (subject 6) showed evidence of a signal above
background on ELISA. The antibody titer did not increase
with repeated doses of adjuvant. Seroconversion to env2-3
(SF2) occurred in 8 of the 11 volunteers who received the
complete immunization series with vaccine.
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Table 1. Results of serologic assays of specimens obtained 1 month after the final dose of
env2-3 (SF2).
Group,
volunteer
no.
3, 12
13
14
15
4, 18
19
20
5, 21
22
23
25
Western blot*
+
±
+
+
±
±
RIBAt
±
+
+
+
+
+
+
ELISA titer:/:
env2-3 (SF2) env2-3 (IIIB) env2-3(Zr6)
<10 <10 <10
<10 <10 <10
22 <10 <10
293 155 192
<10 <10 <10
38 38 62
9 <10 <10
227 222 275
66 74 58
43 44 154
46 22 44
* Reactivity with the gpl20 band: +, strong; ±, weak but visible.
t Chiron recombinant immunoblot assay HIV-216 strip analysis. Reaction was observed with the gpl20-equivalent
band but not with any of the other antigens on the strip (gp41, p31, p24): +, strong; ±, weak but visible.
:j: In instances where a signal was observed with prevaccination sera, the preimmunization background titer was sub-
tracted from the postimmunization values. This was necessary only in the env2-3 (IIIB) and env2-3 (Zr6) EUSAs, which
used antigens that were less pure than the env2-3 (SF2) preparation. Sera with titers indicated as <10 showed no signal
at I: 10 serum dilution, the most concentrated dilution tested.
Group 5 individuals showed the highest and most consis-
tent anti-env2-3 (SF2) antibody responses 4 weeks after the
last vaccination. However, the antibody titers were only 5%-
10% of those induced by natural infection. The env2-3 (SF2)
ELISA titers of 86 serum specimens from HIV-seropositive
individuals were ""100-50,000 (reciprocal dilution) with an
average of 1500-2500 (data not shown).
Table 1 summarizes the results of additional serologic as-
says. The results of RIBA with sera collected 1 month after
the final immunization provide an independent confirmation
of seroconversionto env2-3 (SF2). Seven of the 8 volunteers
showing evidence of env2-3(SF2) seroconversion on ELISA
(but none of the volunteers injected with adjuvant alone) also
reacted with the gpl20-equivalent band on RIBA. Finally, sera
from volunteers scoring positive with the gpl20-equivalent
band did not react with any other HIV antigens on RIBA (data
not shown).
Totest whether sera from volunteers immunized with env2-3
(SF2) cross-reacted with the fully glycosylated gp120, a Bio-
tech/Du Pont Western blot assay with virus was done. Three
volunteers had strong reactivity and three showed weak reac-
tivity with viral gpl20 (table I).
Since the virus used in the Western blot is HIV/HTLV-
illB, these data suggest that reactivity elicited by env2-3
(SF2) is likely to be directed toward regions of gpl20 that
are conserved among multiple HIV-I isolates. This hypothe-
sis was supported bydoing ELISA with env2-3 (SF2)-equiva-
lent molecules from HIV/HTLV-IIIB and HIV (Zr6), which
differ from HIV-l(SF2) in 19% and 26%, respectively, in the
predicted amino acids of their gpl20 polypeptides (see table
I). Cross-reactivity of all of the sera with high titers of anti-
bodies to env2-3 (SF2) was observed with the equivalent mol-
ecules from these two isolates. .
Finally, the sera from env2-3 (SF2)-immunized individu-
als did not neutralize HIV-I(SF2) virus in vitro.
Antigen-specific Tcellproliferation. PBMC proliferative
responses to various gpl20-derived antigens and to five env2-3
(SF2)-unrelated antigens (purified protein derivative, tetanus
toxoid, streptococcal antigen preparation, Candida albicans
antigen preparation, and irradiated allogenic cells) were moni-
tored throughout the trial. The proliferative responses to PHA
Table 2. Antigen-specific peripheral blood mononuclear cell
(PBMC) proliferation responses to HIV-1 recombinant envelope
proteins.
Group
1 2 3 4 5
Weeks (n = 4) (n = 5) (n = 4) (n = 3) (n = 4)
0 0 0 0 0 0
4 0 1 1 0 0
8 0 1 3 0 1
12 NO 1 3 1 1
16 NO 1 3 2 2
20 NO 1 3 0 2
24 0 0 3 1 3
28 0 NO 4 2 NO
32 NO NO 4 NO NO
36 NO NO 4 2 NO
NOTE. ND, not determined. Data are number of subjects positive at number of
weeks after start of trial. PBMC responses were assessed using env2-3 (SF2) only
for groups I and 2 and both env2-3 (SF2) and gpl20 (SF2) for groups 3-5. Numbers
for the vaccine groups refer to responses to gpl20 (SF2). Numbers of responses to
env2-3 (SF2) were equivalent.
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Figure 1. Titers of ELISA-reac-
tive antibodies among trial volun-
teers. Tested sera were diluted 1:10
and by serial twofold dilutions for
antibodies to env2-3(SF2). For this
assay, microtiter plates were coated
with 2 jLg/ml env2-3 (SF). The as-
say protocol has been described pre-
viously [16, 17,31]. Titers reported
correspond to the reciprocal of the
dilution that resulted in an ELISA
signal equivalent to half the maxi-
mum value obtained in the assay.
The maximum value was typically
OD = 1.2. Each sample was assayed
in duplicate and the average shown.
Group 4
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and to these five control antigens remained unchanged
throughout the study in all subjects of all groups (data not
shown). The proliferative responses to env2-3 (SF2) through-
out the study are shown in table 2. Preimmunization T cell
proliferative responses to env2-3 (SF2) were not detected in
either the controls or vaccine recipients. After immunization,
the four subjects of group 3 (three injections of the low-dose
vaccine) developed a T cell proliferative response to env2-3
(SF2), whereas only two of three subjects in group 4 and three
of four in group 5 responded, although they had received the
high dose of vaccine. Also, in the latter two groups, response
occurred later than in group 3.
Surprisingly, the PBMC of subject 6 (group 2, control)
significantly responded to env2-3 (SF2) from week 4 up to
week 20 but appeared nonreactive at week 24. Very low anti-
body titers were also detected in the sera of this subject (figure
1). However, the polymerase chain reaction done 1 year after
the start of study was negative in this subject, suggesting that
serologic and cellular reactions were nonspecific, as has been
reported for serologic testing [33]. This might be due to cross-
reactivity with other microorganisms or to particular physico-
chemical properties of plasma proteins. The PBMC responses
of all other controls remained unreactive during the entire trial
period.
In every case where env2-3 (SF2)-specific proliferation was
observed in individuals receiving vaccine (table 2), it was also
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Table 3. Specific peripheral blood mononuclear cell (PBMC) re-
sponses measured before the first injection and 4 weeks after the
last boost.
Group, Week 0 Week 24/28*
volunteer
no. Medium env2-3 (SF2) Medium env2-3 (SF2)
1, control
1 2.2 4.4 0.1 0.2
2 3.5 4.5 0.1 0.1
3 0.3 0.3 0.1 1.2
5 0.1 0.3 0.9 0.8
2, control
6 0.7 0.6 0.2 0.9
7 0.8 0.7 0.1 0.4
8 0.2 0.5 0.2 0.7
9 0.4 0.4 0.3 0.6
10 0.3 0.3 0.7 0.8
Medium gp120 (SF2) Medium gp120 (SF2)
3, vaccine
12 1.7 2.4 0.1 4.2 (42)
13 4.3 4.4 0.2 4.4 (22)
14 1.0 0.9 0.1 18.1 (181)
15 1.6 1.7 0.1 15.5 (155)
4, vaccine
18 0.9 1.2 0.6 22.2 (37)
19 0.3 0.3 3.1 36.7 (12)
20 0.1 0.2 1.7 1.2
5, vaccine
21 0.1 0.1 0.2 2.0 (10)
22 1.4 0.4 0.2 18.7 (94)
23 0.4 0.8 2.1 2.5
25 0.4 0.2 0.7 2.9
NOTE. Data represent [3H]thymidine uptake (cpm X 10- 3) of PBMC cultured
for 7 days in the absence (medium) or in the presence of 3 ug/ml antigen env2-3
(SF2)/gpI20 (SF2). Bold type indicates significant gpl20 (SF2) responses with stim-
ulation indices in parentheses.
* 28 weeks for groups I, 3, and 4; 24 weeks for groups 2 and 5.
observed when fully glycosylated native gp120 (SF2) was used
(table 3).
Discussion
Clinically, the vaccine used in this phase I trial was well
tolerated. The main side effect was minor, short-lived pain.
Two volunteers were removed from the trial as a result of
injection-related events: one after experiencing vasovagal syn-
cope immediately after injection of adjuvant and another be-
cause of a local hypersensitivity reaction probably due to the
antigen ..There were no significant alterations in the results
of routine laboratory testing. This study also revealed that
MTP-PE at 100 p.gper intramuscular injection was well toler-
ated and caused no undesirable side effects [26, 34].
One of the major concerns about candidate AIDS vaccines
that contain gp120 is the potential for causing impairment of
CD4+ T cell function due to binding of gp120 to CD4 recep-
tors [35, 36]. None of the volunteers who completed the im-
munization series exhibited cellular immunosuppression as
measured by absolute CD4 and CD8 counts and CD4-to-CD8
ratios. In addition, repeated injections of adjuvant alone or
the complete vaccine did not modify the baseline immuno-
logic status of recipients. In particular, no autoimmune reac-
tions were induced, hypergammaglobulinemia through
polyclonal cell activation was not detected, and there were
no alterations in peripheral blood lymphocyte subpopulations
or changes in the cellular immune response to nonspecific
mitogens, allogeneic cells, or environmental antigens.
Immunization resulted in seroconversion to env2-3 (SF2)
in the majority of volunteers. Cross-reactivity with the fully
glycosylated version of HIV-I gp120 was seen in Western blot
assays with sera from those individuals exhibiting the highest
titers of antibodies to env2-3 (SF2). In addition, there was
evidence that these antibodies cross-reacted with envelope an-
tigens from highly divergent HIV-1 isolates. However, we did
not observe any neutralization of HIV-1 infectivity. This was
not surprising, as the antibody titers elicited against env2-3
(SF2) were very low. In fact, in comparison with our ex-
perience using experimental animals immunized with env2-3
(SF2), antibody titers in sera from vaccinees were well be-
low the usual threshold at which neutralization of HIV-1(SF2)
infectivity is observed in vitro.
In contrast to the antibody results, we obtained in part a
strong cellular response in 9 of 11vaccine recipients. The stim-
ulation was more prominent among subjects who received the
low dose of antigen with a rest period of 5 months before the
second boost. The T cells involved in this response recog-
nized not only the env2-3 (SF2) antigen but also the native
glycosylated gp120 (SF2). A detailed account of this study,
including major histocompatibility complex restriction and
the cross-reactivity of both PBMC and gp120-specific T cell
clones with envelope proteins from other HIV isolates, has
been reported elsewhere [37].
The efficacy of a candidate HIV vaccine can be tested only
in a prospective placebo-controlled clinical trial. Before such
trials can be initiated, some indications about the protective
potential of vaccine candidates must be obtained by using in
vitro immunologic assays that are expected to correlate with
in vivo protection. Neutralizing antibodies are thought to play
a role in antiviral activity, but until recently they have not been
shown to prevent infection of experimental animals with the
HIV system [38]. The fact that rhesus monkeys are immune
to the simian immunodeficiency virus after inoculation with
a killed whole-virus vaccine points to the possible importance
of humoral responses in protective immunity. In addition, the
helper T cell responses generated by a soluble antigen may,
on virus infection, play an important role complementing the
antibodies present. Healthy HIV-seropositive individuals have
been known to be depleted of helper CD4+ T cells capable
of recognizing virus-specific antigens, including gp120 [39,
40]. In contrast, some seronegative individuals with HIV-
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infected partners have detectable levels of HIV-specific helper
T cells [41]indicating a possible role for this lymphocyte subset
in protective immunity. An effective HIV vaccine may thus
require both antigen-specific helper T cell responses and the
presence of antibodies with cross-neutralizing properties
against epidemiologically prevalent HIV isolates.
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